Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis…

Overview of attention for article published in Breast Cancer Research, August 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 39 X posts from 29 X users, with an upper bound of 67,690 followers.

RT @LobularBCA: Patients with #lobular NEED MORE and better THERAPY OPTIONS given #ILC is not necessarily chemo responsive. One size fits a…

RT @LobularBCA: Patients with #lobular NEED MORE and better THERAPY OPTIONS given #ILC is not necessarily chemo responsive. One size fits a…

RT @LobularBCA: Patients with #lobular NEED MORE and better THERAPY OPTIONS given #ILC is not necessarily chemo responsive. One size fits a…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 35 additional X posts.